Toshihiko Murayama

Toshihiko Murayama

Auto-generated profile, based on publicly available information

Toshihiko Murayama

Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba 260-8675, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
RYRisa Yamazaki
Risa Yamazaki
Yoshitoshi KasuyaYoshitoshi Kasuya
Yoshitoshi Kasuya
TFTetsuo Fujita
Tetsuo Fujita
HUHiroki Umezawa
Hiroki Umezawa
MYMadoka Yanagihara
Madoka Yanagihara
TMToshihiko Murayama
Toshihiko Murayama
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder that is characterized by aberrant tissue remodeling and the formation of fibroblastic foci that are composed of fibrogenic myofibroblasts. TGF‐β1 is one of the factors that are responsible for fibrosis as it promotes fibroblast to myofibroblast differentiation (FMD) and is associated with up‐regulation of α‐smooth muscle actin. Therefore, inhibition of FMD may represent an effective strategy for the treatment of IPF. Here, we describe the treatment of human lung fibroblasts (WI‐38 and HFL‐1 cells) with cyclosporine A (CsA), which reduces TGF‐β1–induced FMD via degradation of hypoxia‐inducible factor‐1α (HIF‐1α). In addition, in primary myofibroblast‐like cells that were obtained from a patient with pulmonary fibrosis, treatment with CsA and an HIF‐1α inhibitor (HIFi) decreased the expression levels of α‐smooth muscle actin and fibronectin, which indicated that CsA and HIFi promote dedifferentiation of myofibroblasts. In mice intratracheally administered CsA or HIFi at an early fibrotic stage [7, 8, and 9 d postinstillation (dpi) of bleomycin], marked alleviation of lung fibrosis was observed at 14 dpi. These results suggest that CsA exhibits antifibrotic effects by degrading HIF‐1α and that the CsA–HIF‐1α axis provides new insights into therapeutic options for the treatment of IPF.—Yamazaki, R., Kasuya, Y., Fujita, T., Umezawa, H., Yanagihara, M., Nakamura, H., Yoshino, I., Tatsumi, K., Murayama, T. Antifibrotic effects of cyclosporine A on TGF‐β1–treated lung fibroblasts and lungs from bleomycin‐treated mice: role of hypoxia‐inducible factor‐1α. FASEB J . 31, 3359–3371 (2017). www.fasebj.org

15 November 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SNShohei Nishino
Shohei Nishino
HYHisahiro Yamashita
Hisahiro Yamashita
MTMizuki Tamori
Mizuki Tamori
MMMasato Mashimo
Masato Mashimo
KYKazuyuki Yamagata
Kazuyuki Yamagata
TMToshihiko Murayama
Toshihiko Murayama

1 January 2010 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
ETEiko Tada
Eiko Tada
KTKaori Toyomura
Kaori Toyomura
HNHiroyuki Nakamura
Hiroyuki Nakamura
HSHirotsune Sasaki
Hirotsune Sasaki
TSTakeshi Saito
Takeshi Saito
TMToshihiko Murayama
Toshihiko Murayama
Ceramide, a key molecule in the metabolism of sphingolipids, is converted by ceramidase to sphingosine, and phosphorylated by ceramide kinase to form ceramide-1-phosphate (C1P). In this study, we improved on a method of thin-layer chromatography using a fluorescent ceramide, 4-nitrobenzo-2-oxa-1,3-diazole–labeled C6-ceramide (NBD-ceramide) by adding another step for separation of extracted ceramide metabolites by lipophilicity, and determined levels of C1P, caproic acid, sphingomyelin, and glucosylceramide simultaneously. Also we found that 1) treatment of NBD-ceramide–labeled cells (human lung adenocarcinoma A549 cells and Chinese hamster ovary cells) with Na3VO4 increased the amount of NBD-C1P formed within 30 min, 2) the treatment increased production of NBD-caproic acid, a counterpart of sphingosine, by ceramidase within 2 h, 3) expression of ceramide kinase enhanced the Na3VO4-induced formation of NBD-C1P, and tyrosine kinase inhibitors (herbimycin and genistein) decreased the response, 4) the production of NBD-caproic acid in A549 cells was inhibited by genistein, and 5) the responses for 2 h after Na3VO4 treatment were accompanied by a decrease in the production of NBD-sphingomyelin, not a loss of NBD-ceramide. The improved thin-layer chromatography method was useful for the simultaneous determination of enzymatic activities for ceramide metabolism in cells.

23 January 2015 in Traffic
Verified
Journal Article
Open access
PDF file
TMTomohiko Makiyama
Tomohiko Makiyama
HNHiroyuki Nakamura
Hiroyuki Nakamura
NNNobuo Nagasaka
Nobuo Nagasaka
HYHisahiro Yamashita
Hisahiro Yamashita
THTakuya Honda
Takuya Honda
TMToshihiko Murayama
Toshihiko Murayama
The Golgi complex plays a prominent role in the modification and sorting of lipids and proteins, and is a highly dynamic organelle that is dispersed and rearranged before and after mitosis. Several reagents including 4‐nitrobenzo‐2‐oxa‐1,3‐diazole‐labeled C6‐ceramide (NBD‐C6‐ceramide, a ceramide having an NBD‐bound C6‐N‐acyl chain) and Golgi‐specific proteins that emit fluorescence are used as Golgi markers. In the present study, we synthesized a new ceramide analog, acetyl‐C16‐ceramide‐NBD (a ceramide having an acetylated C‐1 hydroxyl group, C16‐N‐acyl chain, and NBD‐bound C15‐sphingosine), and showed that it preferentially accumulated in the Golgi complex without cytotoxicity for over 24 h. Pathways for cellular uptake and interorganelle trafficking of acetyl‐C16‐ceramide‐NBD were investigated. Acetyl‐C16‐ceramide‐NBD was transported to the Golgi complex via ceramide transport proteins. In contrast to NBD‐C6‐ceramide, acetyl‐C16‐ceramide‐NBD was resistant to ceramide metabolic enzymes such as sphingomyelin synthase and glucosylceramide synthase. Because of its weaker cytotoxicity and resistance to ceramide metabolic enzymes, the localization of the Golgi complex could be observed in acetyl‐C16‐ceramide‐NBD‐labeled cells before and after mitosis.

26 April 2017 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HNHiroyuki Nakamura
Hiroyuki Nakamura
YMYuta Moriyama
Yuta Moriyama
KWKazuaki Watanabe
Kazuaki Watanabe
STSatoshi Tomizawa
Satoshi Tomizawa
RYRisa Yamazaki
Risa Yamazaki
TMToshihiko Murayama
Toshihiko Murayama

1 October 2014 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SYSatoshi Yamane
Satoshi Yamane
TKToshio Kanno
Toshio Kanno
HNHiroyuki Nakamura
Hiroyuki Nakamura
HFHiromichi Fujino
Hiromichi Fujino
TMToshihiko Murayama
Toshihiko Murayama